STOCK TITAN
  1. Home
  2. News
  3. ONCY

Oncolytics Biotech, Inc. - ONCY STOCK NEWS

Welcome to our dedicated news page for Oncolytics Biotech (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncolytics Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncolytics Biotech's position in the market.

News
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) reported significant 2023 accomplishments, positive clinical and translational data, and anticipated milestones for 2024. The company's cash balance of $40 million supports the initiation of the first Phase 3 study for pelareorep in pancreatic cancer, marking an important inflection point for investors and clinical collaborators. Positive results from Phase 1/2 GOBLET study and HR+/HER2- metastatic breast cancer program demonstrate the potential of pelareorep as an immunotherapeutic agent for various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
News
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented translational data from the AWARE-1 breast cancer study at the San Antonio Breast Cancer Symposium. The data showed that pelareorep induced the expansion of Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor, affirming its role as an immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
News
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announces positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA). The interim objective response rate (ORR) of 37.5% exceeded historical control trials, showing the potential for pelareorep to offer a new, effective treatment option for patients with advanced SCCA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
clinical trial
News
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC). The company will conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study. PanCAN will grant US$5 million for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
none
-
News
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
Rhea-AI Summary
Oncolytics Biotech announces positive translational data from the AWARE-1 breast cancer study, confirming pelareorep's mechanism of action in the tumor microenvironment. The data shows an increase in PD-L1 positive cells and T cell infiltration after treatment. This supports the use of pelareorep in combination with atezolizumab for metastatic breast cancer and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
-
News
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Oncolytics Biotech announced positive Phase 1/2 survival data for pelareorep in pancreatic cancer. The data showed an objective response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. The company also received a $5 million grant from Pancreatic Cancer Action Network to further evaluate pelareorep in pancreatic cancer. The cash position is $40.0 million with a projected cash runway through critical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
earnings
News
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
Rhea-AI Summary
Oncolytics Biotech announces positive results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at ESMO 2023. The study shows an overall response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. T-cell expansion data correlate with tumor response. The treatment combination has been well tolerated with no safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
clinical trial
-
News
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Rhea-AI Summary
Oncolytics Biotech announces positive interim results from the Phase 1/2 GOBLET study evaluating pelareorep in patients with third-line metastatic colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
-
News
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Rhea-AI Summary
Oncolytics Biotech to host conference call and webcast on November 3, 2023, to discuss corporate update and financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
conferences earnings
News
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
Rhea-AI Summary
Oncolytics Biotech announces the publication of two abstracts for posters to be presented at the ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
Stock ONCY logo
Oncolytics Biotech, Inc.

Nasdaq:ONCY

ONCY Rankings

#4446 Ranked by Market Cap
#846 Ranked by Stock Gains
N/A Ranked by Dividends

ONCY Stock Data

85.98M
66.96M
6.16%
6.88%
1.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Calgary

About ONCY

oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.